Open Wed 8:30am : 01582 842096
VioVet Insurance
FREE DELIVERY on most orders over £29

Onsior for Dogs & Cats

  • Cat 6mg » Priced per Tablet £0.52
  • Dog 5mg » Priced per Tablet £0.36
  • Dog 10mg » Priced per Tablet £0.51
  • Dog 20mg » Priced per Tablet £0.72
  • Dog 40mg » Priced per Tablet £0.94
  • Solution for Injection » 20mg/ml £45.06

Selection of 6 products from

£0.36 to £45.06

Description

Onsior is one of the safest medications of its type for use in dogs and cats. For dogs it is used primarily to treat osteoarthritis (degenerative joint disease). Onsior reduces pain and stiffness in the joints of affected dogs, increasing their mobility and enjoyment of exercise. Onsior can also be an effective treatment for the relief of pain and inflammation of other causes in both dogs and cats. Its effects are directed particularly at the causes of the inflammation meaning that side effects are much less likely to occur.

Onsior should not be given to patients which are dehydrated, or if underlying kidney or gastro-intestinal conditions might be present. Treatment should be supended if vomiting or diarrhoea are seen.

Onsior 5 mg, 10 mg, 20 mg, 40 mg flavoured tablets for dogs

Presentation

Round, beige to brown non-divisible tablets with the imprint "NA" on one side and the following imprint on the other side: AK (5 mg tablet), BE (10 mg tablet), CD (20 mg tablet) and BCK (40 mg tablet).

Each tablet of Onsior 5, 10, 20 and 40 respectively contains as active ingredient robenacoxib 5 mg, 10 mg, 20 mg and 40 mg.

The tablets are palatable (flavoured with yeast and artificial beef) and are taken voluntarily by most dogs.

Uses

Onsior is a non-steroidal anti-inflammatory drug (NSAID) for use in dogs. Robenacoxib is part of the coxib class of NSAIDs and is recommended for the treatment of pain and inflammation associated with chronic osteoarthritis in dogs.

Robenacoxib is a potent and selective inhibitor of the cyclooxygenase 2 enzyme (COX-2). The cyclooxygenase enzyme (COX) is present in two forms. COX-1 is the constitutive form of the enzyme and has protective functions, e.g. in the gastrointestinal tract and kidneys. COX-2 is the inducible form of the enzyme and is responsible for the production of mediators including prostaglandin E2 (PGE2) which induce pain, inflammation or fever.

In an in vitro whole blood assay in dogs, robenacoxib was approximately 140-fold selective for COX-2 as compared to COX-1. Robenacoxib produced marked inhibition of COX-2 activity and had no effect on COX-1 activity in dogs at oral doses ranging from 0.5 to 4 mg/kg. Robenacoxib tablets are therefore COX-1 sparing at recommended doses in dogs. Robenacoxib had analgesic and anti-inflammatory actions in an inflammation model in dogs with single oral doses ranging from 0.5 to 8 mg/kg, with a rapid onset of action (0.5h). In clinical trials robenacoxib tablets reduced the lameness and inflammation of dogs with chronic osteoarthritis.

After oral administration of robenacoxib flavoured tablets at 1 mg/kg without food, peak blood concentrations are attained rapidly with a Tmax of 0.5 hour. Co-administration of robenacoxib non-flavoured tablets with food produced no delay in Tmax but slightly lower values for peak blood concentrations.

Robenacoxib is highly bound to plasma proteins (>99%) and is extensively metabolised by the liver in dogs. Robenacoxib is cleared rapidly from the blood: after oral administration of the tablets, the terminal half-life in blood was 1.2 hour. Robenacoxib persists longer and at higher concentrations at sites of inflammation than in blood. Robenacoxib is excreted predominately via the biliary route (~65%) and the remainder via the kidneys. Repeated oral administration of robenacoxib to dogs at dosages of 2 -10 mg/kg for 6 months produced no change in blood profile, with neither accumulation of robenacoxib nor enzyme induction.

Dosage and administration

For oral use. Do not administer with food since clinical trials demonstrated better efficacy of robenacoxib when administered without food or at least 30 minutes before or after a meal. The tablets should not be divided or broken.

The recommended dose of robenacoxib is 1 mg/kg body weight with a range of 1-2 mg/kg. Administer once daily at the same time every day according to the table below.

Bodyweight (kg)

Number of tablets

5 mg

10 mg

20 mg

40 mg

2.5 to<5

1 tablet

5 to <10

1 tablet

10 to <20

1 tablet

20 to <40

1 tablet

40 to 80

2 tablets

A clinical response is normally seen within a week. Treatment should be discontinued after 10 days if no clinical improvement is apparent.

For long term treatment, once clinical response has been observed, the dose of Onsior can be adjusted to the lowest effective individual dose reflecting that the degree of pain and inflammation associated with chronic osteoarthritis may vary over time. Regular monitoring should be undertaken by the veterinarian.

Contra-indications, warnings, etc

Do not use in dogs suffering from gastrointestinal ulceration or with hepatic disease. Do not use concomitantly with corticosteroids or other non-steroidal anti-inflammatory drugs (NSAIDs). Do not use in case of hypersensitivity to the active substance or to any of the excipients. In clinical studies, inadequate response to treatment was seen in 10-15% of the dogs. Because the safety of robenacoxob has not been established during pregnancy and lactation or in dogs used for breeding, Onsior is not recommended for use in pregnant or lactating dogs.

The safety of the veterinary medicinal product has not been established in dogs weighing less than 2.5 kg or under 3 months of age.

For long term therapy, liver enzymes should be monitored at the start of therapy, e.g. after 2, 4 and 8 weeks. Thereafter it is recommended to continue regular monitoring , e.g. every 3-6 months. Therapy should be discontinued if liver enzyme activities increase markedly or the dog shows clinical signs such as anorexia, apathy or vomiting in combination with elevated liver enzymes. In dogs treated up to 2 weeks no increases in liver enzyme activities were observed. However, with long term treatment, increases in liver enzyme activities were common. In most cases there were no clinical signs and the liver enzyme activities either stablilised or decreased with continued treatment. Increases in liver enzyme activities associated with clinical signs of anorexia, apathy or vomiting were uncommon.

Use in dogs with impaired cardiac, or renal function or dogs that are dehydrated, hypovolaemic or hypotensive may involve additional risks. If use cannot be avoided, these dogs require careful monitoring.

Gastrointestinal adverse events were reported very commonly, but most cases were mild and recovered without treatment. Vomiting and soft faeces were very common, decreased appetite and diarrhoea were common, and blood in the faeces was uncommon.

Use this product under strict veterinary monitoring in dogs with a risk of gastrointestinal ulcers, or if the dog previously displayed intolerance to other NSAIDs.

Onsior must not be administered in conjunction with other NSAIDs. Pre-treatment with other anti-inflammatory medicines may result in additional or increased adverse effects and accordingly a treatment-free period with such substances should be observed for at least 24 hours before the commencement of treatment with Onsior. The treatment-free period, however, should take into account the pharmacokinetic properties of the products used previously.

Concomitant treatment with medicines displaying action on renal flow, e.g. diuretics or angiotensin converting enzyme (ACE) inhibitors, should be subject to clinical monitoring.

Concurrent administration of potentially nephrotoxic medicines should be avoided as there might be an increased risk of renal toxicity.

Concurrent use of other active substances that have a high degree of protein binding may compete with robenacoxib for binding and thus lead to toxic effects.

Pharmaceutical precautions

Do not store above 25°C.

Wash hands after use of the veterinary medicinal product.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician. In small children, accidental ingestion increases the risk for NSAID adverse effects.

For pregnant women, particularly near term pregnant women, prolonged dermal exposure increases the risk of premature closure of the ductus arteriosus in the foetus.

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Legal category

POM-V

Packaging Quantities

Cardboard box containing 1, 2, 4 or 10 Alu/Alu blisters. Each blister contains 7 tablets.

Further information

In healthy young dogs aged 5-6 months, oral robenacoxib administered at high overdosed (4, 6, or 10 mg/kg/day for 6 months) did not produce any signs of toxicity, including no evidence of any gastrointestinal, kidney or liver toxicity and no effect on bleeding time. Robenacoxib also had no detrimental effects on cartilages or joints.

As with any NSAID, overdose may cause gastrointestinal, kidney, or liver toxicity in sensitive or compromised dogs. There is no specific antidote. Symptomatic, supportive therapy is recommended consisting of administration of gastrointestinal protective agents and infusion of isotonic saline.

Marketing authorisation number

EU/2/08/089/004-019.

Onsior 6 mg flavoured tablets for Cats

Presentation

Round, beige to brown non-divisible tablets with imprints "NA" on one side and "AK" on the other side.

Each tablet contains 6 mg robenacoxib as active ingredient.

The tablets are palatable (yeast flavoured), easy to administer and well accepted by most cats.

Uses

Onsior is a non-steroidal anti-inflammatory drug (NSAID) for use in cats. Robenacoxib is part of the coxib class of NSAIDs and is recommended for the treatment of acute pain and inflammation associated with musculoskeletal disorders in cats. Onsior is also recommended for the reduction of moderate pain and inflammation associated with orthopaedic surgery in cats.

Robenacoxib is a potent and selective inhibitor of the cyclooxygenase 2 enzyme (COX-2). The cyclooxygenase enzyme (COX) is present in 2 forms. COX-1 is the constitutive form of the enzyme and has protective functions, e.g. in the gastrointestinal tract and kidneys. COX-2 is the inducible form of the enzyme which is responsible for the production of mediators including prostaglandin E2 (PGE2) which induce pain, inflammation or fever.

In the in vitro whole blood assay in cats, robenacoxib was approximately 500 fold selective for COX-2 as compared to COX-1. 1-2 mg/kg robenacoxib tablets produced a marked inhibition of COX-2 activity in cats and had no effect on COX-1 activity.

After oral administration of robenacoxib tablets at approximately 2 mg/kg without food, peak blood concentrations are attained rapidly with a Tmax of 0.5 h. Co-administration of robenacoxib tablets with one third of the daily food ration produced no change in Tmax (0.5 h).

Robenacoxib is highly bound to plasma proteins (>99%) and extensively metabolised by the liver in cats. It is rapidly cleared from blood. After oral administration of tablets, the terminal half-life from blood was 1.7h. Robenacoxib persists longer and at higher concentrations at sites of inflammation that in blood. Robenacoxib is excreted predominantly via the biliary route (~70%) rather than via the kidneys (~30%).

Dosage and administration

For oral use. Give either without food or with a small amount of food. The tablets should not be divided or broken.

The recommended dose of robenacoxib is 1 mg/kg body weight with a range 1-2.4 mg/kg.

The following number of tablets should be given once daily at the same time every day.

Body weight (kg)

Number of tablets

2.5 to < 6

1 tablet

6 to < 12

2 tablets

For acute musculoskeletal disorders treat for up to 6 days.

Orthopaedic surgery:

Give as a single oral treatment prior to orthopaedic surgery.

Premedication should only be carried out in combination with butorphanol-analgesia. The tablet(s) should be administered without food at least 30 minutes prior to surgery.

After surgery, once daily treatment may be continued for up to two further days. If necessary, additional analgesic treatment with opioids is recommended.

Contra-indications, warnings, etc

Do not use in cats suffering from gastrointestinal ulceration. Do not use concomitantly with corticosteroids or other non-steroidal anti-inflammatory drugs (NSAIDs). Do not use in case of hypersensitivity to the active substance or to any of the excipients. Because the safety of robenacoxib has not been established during pregnancy and lactation or in cats used for breeding it is therefore not recommended for use in pregnant and lactating animals.

The safety of the veterinary medicinal product has not been established in cats weighing less than 2.5 kg or under 4 months of age.

Use in cats with impaired cardiac, renal or hepatic function or in cats that are dehydrated, hypovolaemic or hypotensive may involve additional risks. If use cannot be avoided, these cats require careful monitoring.

Use this veterinary medicinal product under strict veterinary monitoring in cats with a risk of gastrointestinal ulcers, or if the cat previously displayed intolerance to other NSAIDs.

Mild and transient diarrhoea, soft faeces or vomiting were commonly reported. In very rare cases, lethargy may be observed.

Onsior must not be administered in conjunction with other NSAIDs. Pre-treatment with other anti-inflammatory medicines may result in additional or increased adverse effects and, accordingly a treatment-free period with such substances should be observed for at least 24 hours before the commencement of treatment with Onsior. The treatment-free period, however, should take into account the pharmacokinetic properties of the products used previously.

Concomitant treatment with medicines displaying action on renal flow, e.g. diuretics or angiotensin converting enzyme (ACE) inhibitors, should be subject to clinical monitoring. Concurrent administration of potentially nephrotoxic medicines should be avoided as there might be an increased risk of renal toxicity. Concurrent use of other active substances that have a high degree of protein binding may compete with robenacoxib for binding and thus lead to toxic effects.

Pharmaceutical precautions

Store below 25°C.

Wash hands after use of the veterinary medicinal product. In small children, accidental ingestion increases the risk for NSAID adverse effects. In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician. For pregnant women, particularly near term pregnant women, prolonged dermal exposure increases the risk for premature closure of the ductus arteriosus in the foetus.

Legal category

POM-V

Packaging Quantities

Cardboard box containing 1, 2, 5 or 10 Alu/Alu blisters. Each blister contains 6 tablets.

Any unused medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Further information

In healthy young cats aged 7-8 months, oral robenacoxib administered at high overdoses (4, 12, or 20 mg/kg/day for 6 weeks) did not produce any signs of toxicity, including no evidence of any gastrointestinal, kidney or liver toxicity and no effect on bleeding time.

As with any NSAID, overdose may cause gastrointestinal, kidney, or liver toxicity in sensitive or compromised cats. There is no specific antidote. Symptomatic, supportive therapy is recommended and should consist of administration of gastrointestinal protective agents and infusion of isotonic saline.

Marketing authorisation number

EU/2/08/089/001-003.

EU/2/08/089/021.

Need help or advice? Contact us:

  • Landline: 01582 842096
  • Freephone*: 0800 084 2608
  • Mon - Fri: 8:30am - 6:00pm
  • Sat: 9:00am - 1:00pm
  • Email: support@viovet.co.uk

All prices include VAT where applicable. *The freephone number is free from most UK landlines only, mobiles are usually charged so we'd recommend calling our landline from your mobile or internationally.

Reviews of Onsior for Dogs & Cats

Read our customers' reviews of Onsior for Dogs & Cats

Questions & Answers for Onsior for Dogs & Cats

Below are some recent questions we've received regarding Onsior for Dogs & Cats, including answers from our team.

Ask Your Own Question

Onsior or Previcox

13th Jul 2016
Cherry Welsh
  • VioVet Customer Since: June 2015
  • From: Argyll and Bute, United Kingdom

I would be grateful if you could tell me if there is any significant difference between these 2 drugs regarding their safety and effectiveness in treating osteoarthritis.

My dog had Onsior for a few weeks and it didn't seem to make much difference.

With thanks

John Cousins
  • Veterinary Surgeon

These are both effective normally at reducing the discomfort from osteoarthritis. I am not aware of any scientific investigations conducted to try and compare them in this way, but they are both generally regarded as about equally safe and effective based on anecdotal evidence. Some dogs might happen to respond better to one drug than another, but I do not think that is particularly likely. I would have to question if the symptoms you are noticing are genuinely caused by the osteoarthritis which has been identified. Obviously I cannot tell and indeed it might be very difficult to be sure, but I would say that sometimes osteoarthritis can exist without causing obvious trouble for the dog. Another, unidentified condition could be causing trouble now, rather than the osteoarthritis. My first suggestion would be to re-evaluate the diagnosis, which obviously means going back to your vet. If nothing else is identified, then perhaps just try a different drug as well as doing all you can in other ways to help. Joint supplements such as Yumove or Joint Force are widely believed to be able to help. It is also helpful to encourage regular, gentle exercise (but never excited, strenuous or prolonged). Weight loss through food reduction is for some dogs the most beneficial thing you can do, but that depends on the current bodyweight and other factors. All else being equal though, you aim for a slim dog. It is always possible through simply giving less food, but that is very difficult for many people in practice.

Yumove

19th Dec 2015
Neil

Can this be given at the same time as yumove?

John Cousins
  • Veterinary Surgeon

It is very common to use a prescription, anti-inflammatory drug such as Onsior along with a non-prescription, joint supplement such as Yumove. Many vets do recommend this and it is safe. Other measures can involve restricting food levels a bit to help keep body weight down as well as encouraging regular but gentle exercise.

Onsior overdose?

21st Apr 2015
Gilly Peters

Hector is on constant Onsior, 1 tablet per day, but today we both inadvertently dosed him, so he has taken 2. Could this be dangerous? He seems hyper and a bit "whiney" (He is a 30kg Lab/lurcher).

John Cousins
  • Veterinary Surgeon

This is unlikely to cause trouble, but it certainly could. If your dog shows any vomiting or diarrhoea it is important not to give any more tablets and go straight to your vet. If he seems fine then all should be well. I would be tempted to miss out the next dose though.

Extra Tablets

23rd Feb 2015
Deanna

Hello there
My dog has just been diagnosed with Elbow Dysplasia and has been given these Onsior tablets (40mg) to take.
We was wondering if we can also give him some herbal tablets too, as we gave him them before and seemed to help him, however we do not want any weird side effects.
Thank you for your help
Deanna Miller

John Cousins
  • Veterinary Surgeon

Most herbal tablets appear to be safe and can be given alongside Onsior, but they have not all been tested and there is no scientific confirmation of that initial comment. Personally I would be happy for you to give any of the main brand herbal products at the recommended amount alongside Onsior. As long as your dog is otherwise well, it is very unlikely that there would be any sort of adverse reaction.The glucosamine/chondroitin based supplements, such as Joint Force, are regarded as particularly suitable to add to the treatment.

Hair loss

6th May 2014
Lexie

My dog has been taking on onsior and is doing her leg good, can you please tell me if it has any side effects as she is losing her coat, it started with a lilltle bald patch on her back but now it's coming out on her chest
Please help
Thank you

John Cousins
  • Veterinary Surgeon

Onsior can occasionally have side effects, but hair loss is very unlikely to be due to the Onsior. It is much more likely to be a coincidence that the hair loss is occurring at the same time. I would make sure that your flea control measures are adequate, even if you see no fleas, and take your cat to the vet to be checked out for any other causes. (A flea allergy would be a very common cause for hair loss on cats, and can happen with very few fleas which are difficult to see.)